Docosahexaenoic acid enhances the toxic effect of imatinib on Bcr-Abl expressing HL-60 cells.
The effect of docosahexaenoic acid (DHA) on the killing efficacy of imatinib on HL-60 cells expressing the Bcr-Abl protein was investigated. Imatinib is an Abl tyrosine kinase inhibitor used in the treatment of patients with chronic myeloid leukemia. The pre-treatment with DHA for 24 h raised the effect of imatinib at 100 microM concentration only. On the other hand, after 72 h pre-treatment, all concentrations of DHA tested (25, 50 and 100 microM) enhanced the toxic effect of imatinib. These results indicate that long-term pre-treatment with DHA makes Bcr-Abl HL-60 cells more susceptible to the toxic effect of imatinib.
de Lima
Thais Martins
TM
Department of Physiology and Biophysics, Institute of Biomedical Sciences, University of São Paulo, Av. Prof Lineu Prestes, 1524, 05508-900 São Paulo, Brazil. thais@icb.usp.br
Amarante-Mendes
Gustavo P
GP
Curi
Rui
R
D000970:Antineoplastic Agents / Q000633:toxicity*; D001549:Benzamides; D004281:Docosahexaenoic Acids / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D005786:Gene Expression Regulation; D016313:Genes, abl / Q000235:genetics*; D018922:HL-60 Cells; D006801:Humans; D000068877:Imatinib Mesylate; D010879:Piperazines / Q000819:agonists* / Q000633:toxicity*; D011743:Pyrimidines / Q000819:agonists* / Q000633:toxicity*
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D004281:Docosahexaenoic Acids; D000068877:Imatinib Mesylate